Meiji Holdings Co Ltd
TSE:2269

Watchlist Manager
Meiji Holdings Co Ltd Logo
Meiji Holdings Co Ltd
TSE:2269
Watchlist
Price: 3 144 JPY 0.48%
Market Cap: 887.2B JPY
Have any thoughts about
Meiji Holdings Co Ltd?
Write Note

Meiji Holdings Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Meiji Holdings Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Meiji Holdings Co Ltd
TSE:2269
Interest Income Expense
ÂĄ24.9B
CAGR 3-Years
84%
CAGR 5-Years
N/A
CAGR 10-Years
47%
Yakult Honsha Co Ltd
TSE:2267
Interest Income Expense
ÂĄ21.5B
CAGR 3-Years
15%
CAGR 5-Years
11%
CAGR 10-Years
12%
Ajinomoto Co Inc
TSE:2802
Interest Income Expense
ÂĄ2.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Kikkoman Corp
TSE:2801
Interest Income Expense
ÂĄ9.8B
CAGR 3-Years
69%
CAGR 5-Years
16%
CAGR 10-Years
10%
Nissin Foods Holdings Co Ltd
TSE:2897
Interest Income Expense
ÂĄ14.7B
CAGR 3-Years
38%
CAGR 5-Years
19%
CAGR 10-Years
4%
Toyo Suisan Kaisha Ltd
TSE:2875
Interest Income Expense
ÂĄ8.4B
CAGR 3-Years
101%
CAGR 5-Years
30%
CAGR 10-Years
26%
No Stocks Found

Meiji Holdings Co Ltd
Glance View

Market Cap
868.4B JPY
Industry
Food Products

Meiji Holdings Co., Ltd. has long been a staple in the world of Japanese consumer goods, specifically in the food and pharmaceutical sectors. Established in 2009 as a result of merging Meiji Seika Kaisha, Ltd. and Meiji Dairies Corporation, the company stands as a testament to the power of strategic consolidation, leveraging over a century of expertise from its predecessors. The company's robust product portfolio spans a diverse array of offerings, including dairy products like yogurts and milk, confectioneries like chocolate and candy, as well as nutrition bars and supplements. This triumvirate of product lines allows Meiji Holdings to position itself in both the everyday consumer market and in specialized health-centric industries, exploiting economies of scale and extensive distribution networks that reach far beyond the Japanese archipelago. In the pharmaceutical arena, Meiji Holdings operates under its subsidiary, Meiji Seika Pharma, focusing predominantly on antibacterial drugs, central nervous system treatments, and veterinary products. By integrating research and development with a comprehensive marketing strategy, the company capitalizes on global health trends and regional disease challenges, expanding in markets that emphasize health and dietary improvements. Financially, Meiji Holdings generates revenue by producing goods that tap into both traditional consumer desires and modern nutritional trends. It makes money by introducing high-margin pharmaceutical innovations alongside its well-established consumer brands, thus benefiting from both everyday sales and solutions aimed at pressing global health needs. Together, these strategic components make Meiji Holdings an agile player in a competitive global market, combining heritage with innovation.

Intrinsic Value
4 294.01 JPY
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Meiji Holdings Co Ltd's Interest Income Expense?
Interest Income Expense
24.9B JPY

Based on the financial report for Jun 30, 2024, Meiji Holdings Co Ltd's Interest Income Expense amounts to 24.9B JPY.

What is Meiji Holdings Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
47%

The average annual Interest Income Expense growth rates for Meiji Holdings Co Ltd have been 84% over the past three years , and 47% over the past ten years .

Back to Top